These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12353074)

  • 21. Novel FV mutation (W1920R, FVNara) associated with serious deep vein thrombosis and more potent APC resistance relative to FVLeiden.
    Nogami K; Shinozawa K; Ogiwara K; Matsumoto T; Amano K; Fukutake K; Shima M
    Blood; 2014 Apr; 123(15):2420-8. PubMed ID: 24523236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proposal for objective evaluation of the performance of various functional APC-resistance tests in genotyped patients.
    Freyburger G; Javorschi S; Labrouche S; Bernard P
    Thromb Haemost; 1997 Nov; 78(5):1360-5. PubMed ID: 9408020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The factor V R2 allele: risk of venous thromboembolism, factor V levels and resistance to activated protein C.
    Luddington R; Jackson A; Pannerselvam S; Brown K; Baglin T
    Thromb Haemost; 2000 Feb; 83(2):204-8. PubMed ID: 10739373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The factor V HR2 haplotype and the risk of venous thrombosis: a meta-analysis.
    Castaman G; Faioni EM; Tosetto A; Bernardi F
    Haematologica; 2003 Oct; 88(10):1182-9. PubMed ID: 14555316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Probability of recurrence of thrombosis in patients with and without factor V Leiden.
    Rintelen C; Pabinger I; Knöbl P; Lechner K; Mannhalter C
    Thromb Haemost; 1996 Feb; 75(2):229-32. PubMed ID: 8815565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The factor V (FV) gene ASP79HIS polymorphism modulates FV plasma levels and affects the activated protein C resistance phenotype in presence of the FV Leiden mutation.
    Bossone A; Cappucci F; D'Andrea G; Brancaccio V; Cibelli G; Iannaccone L; Grandone E; Margaglione M
    Haematologica; 2003 Mar; 88(3):286-9. PubMed ID: 12651267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Method-dependent influence of certain polymorphisms in the factor V B-domain on the response to activated protein C.
    Siegert G; Kostka H; Gehrisch S; Schwarz T; Schellong S; Jaross W
    Blood Coagul Fibrinolysis; 2000 Sep; 11(6):519-27. PubMed ID: 10997791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
    Gessoni G; Valverde S
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does activated protein C-resistant factor V contribute to thrombin generation in hemophilic plasma?
    Bos MH; Meijerman DW; van der Zwaan C; Mertens K
    J Thromb Haemost; 2005 Mar; 3(3):522-30. PubMed ID: 15748243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Homozygous factor V-deficient patients show resistance to activated protein C whereas heterozygotes do not.
    Simioni P; Girolami A
    Blood Coagul Fibrinolysis; 1994 Oct; 5(5):825-7. PubMed ID: 7865690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The anticoagulant function of coagulation factor V.
    Cramer TJ; Gale AJ
    Thromb Haemost; 2012 Jan; 107(1):15-21. PubMed ID: 22116556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activated protein C resistance: molecular mechanisms.
    Griffin JH; Heeb MJ; Kojima Y; Fernández JA; Kojima K; Hackeng TM; Greengard JS
    Thromb Haemost; 1995 Jul; 74(1):444-8. PubMed ID: 8578503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modified APC-resistance test: variable ratios with respect to source of factor V-deficient plasma.
    Ts'ao C; Neofotistos D; Oropeza M; Vahabinejad S; Finn WG
    Am J Hematol; 1997 Mar; 54(3):214-8. PubMed ID: 9067500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endogenous factor V synthesis in megakaryocytes contributes negligibly to the platelet factor V pool.
    Thomassen MC; Castoldi E; Tans G; Magdeleyns EJ; Delaunoit C; Debusscher L; Van Assche KJ; Rosing J
    Haematologica; 2003 Oct; 88(10):1150-6. PubMed ID: 14555311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. APC resistance: biological basis and acquired influences.
    Castoldi E; Rosing J
    J Thromb Haemost; 2010 Mar; 8(3):445-53. PubMed ID: 20002539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.
    Graf LL; Welsh CH; Qamar Z; Marlar RA
    Am J Clin Pathol; 2003 Jan; 119(1):52-60. PubMed ID: 12520697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Study on activated protein C resistance and disordered coagulation in patients with myeloproliferative neoplasms].
    Bai J; Xue YP; Xu XH; Zhang L; Tian MS; Shen L; Zhang HY; Yang RC
    Zhonghua Xue Ye Xue Za Zhi; 2011 Mar; 32(3):187-90. PubMed ID: 21535958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.
    Curvers J; Thomassen MC; Rimmer J; Hamulyak K; van der Meer J; Tans G; Preston FE; Rosing J
    Thromb Haemost; 2002 Jul; 88(1):5-11. PubMed ID: 12152677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of thrombin formation by activated protein C: effect of the factor V Leiden mutation.
    Tans G; Nicolaes GA; Rosing J
    Semin Hematol; 1997 Jul; 34(3):244-55. PubMed ID: 9241709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency of polymorphisms in the B-domain of factor V gene in APC-resistant patients.
    Kostka H; Siegert G; Schwarz T; Gehrisch S; Kuhlisch E; Schellong S; Jaross W
    Thromb Res; 2000 Sep; 99(6):539-47. PubMed ID: 10974338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.